International Trial of Efficacy of Cytoflavin in Head Trauma

PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

November 22, 2020

Primary Completion Date

May 7, 2024

Study Completion Date

September 24, 2024

Conditions
Head Trauma,Closed
Interventions
DRUG

Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)

20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.

DRUG

Placebo

20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days

Trial Locations (8)

197706

City Hospital of the Holy Martyr Elizabeth, Saint Petersburg

030012

West Kazakhstan Medical University named after. M. Ospanov, Aktobe

Unknown

Ivanovskaya Regional Clinical Hospital, Ivanovo

City Clinical Hospital No. 67 named after L.A. Vorokhobov, Moscow

Research Institute of Emergency Medicine n.a. N.V. Sklifosovsky, Moscow

Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko, Nizhny Novgorod

Stavropol Regional Clinical Hospital, Stavropol

"State Autonomous Healthcare Institution of the Sverdlovsk Region Central City Clinical Hospital No. 23", Yekaterinburg

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY

NCT04631484 - International Trial of Efficacy of Cytoflavin in Head Trauma | Biotech Hunter | Biotech Hunter